{
    "address": "Medicinaregatan 8A",
    "city": "Goeteborg",
    "country": "SE",
    "currency": "SEK",
    "cusip": "W87479106",
    "description": "Stayble Therapeutics AB develops an injectable treatment against chronic low back pain triggered by disc degeneration. The company is headquartered in Goeteborg, Vastra Gotalands. The company went IPO on 2020-03-09. The solutions are offered to the patients whose back pain persists after physiotherapy and drugs. The injection is given once and the effect is expected to remain throughout the patient's life and requires minimal rehabilitation. Main focus of the Company is to develop STA363 as a new way of treatment for patients suffering from chronic disc-related low back pain. The firm operates worldwide.",
    "employeeTotal": "",
    "exchange": "NASDAQ OMX NORDIC",
    "finnhubIndustry": "N/A",
    "ggroup": "N/A",
    "gind": "N/A",
    "gsector": "N/A",
    "gsubind": "N/A",
    "ipo": "2020-03-09",
    "isin": "SE0013513652",
    "logo": "",
    "marketCapitalization": 114.0986,
    "naics": "Scientific Research and Development Services",
    "naicsNationalIndustry": "Research and Development in Biotechnology",
    "naicsSector": "Professional, Scientific, and Technical Services",
    "naicsSubsector": "Professional, Scientific, and Technical Services",
    "name": "Stayble Therapeutics AB",
    "phone": "46730808397.0",
    "sedol": "BLCH2Q5",
    "shareOutstanding": 13.846924,
    "state": "VASTRA GOTALANDS",
    "ticker": "STABL.ST",
    "weburl": "http://www.staybletherapeutics.com/"
}